Core Laboratories - CLB Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Core Laboratories in the last twelve months. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "sell" CLB shares.
View CLB analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12 month price objectives for Core Laboratories' shares. Their CLB share price forecasts range from $20.00 to $32.00. On average, they anticipate the company's share price to reach $23.33 in the next year. This suggests a possible upside of 42.8% from the stock's current price.
View analysts price targets for CLB or view top-rated stocks among Wall Street analysts.

Core Laboratories' stock was trading at $22.31 at the beginning of 2022. Since then, CLB shares have decreased by 26.8% and is now trading at $16.33.
View the best growth stocks for 2022 here.

Core Laboratories saw a decline in short interest in July. As of July 31st, there was short interest totaling 4,590,000 shares, a decline of 11.2% from the July 15th total of 5,170,000 shares. Based on an average daily volume of 459,400 shares, the days-to-cover ratio is currently 10.0 days. Approximately 10.0% of the company's stock are sold short.
View Core Laboratories' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our CLB earnings forecast.

Core Laboratories (NYSE:CLB) announced its quarterly earnings data on Wednesday, July, 27th. The oil and gas company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.14 by $0.02. The oil and gas company had revenue of $120.90 million for the quarter, compared to the consensus estimate of $121.35 million. Core Laboratories had a net margin of 1.82% and a trailing twelve-month return on equity of 16.12%. Core Laboratories's revenue was up 1.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.18 EPS.

Core Laboratories declared a quarterly dividend on Friday, July 29th. Shareholders of record on Monday, August 8th will be paid a dividend of $0.01 per share on Monday, August 29th. This represents a $0.04 annualized dividend and a yield of 0.24%. The ex-dividend date is Friday, August 5th.
Read our dividend analysis for CLB.

Core Laboratories (NYSE:CLB) pays an annual dividend of $0.04 per share and currently has a dividend yield of 0.25%. The dividend payout ratio is 21.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CLB will have a dividend payout ratio of 4.21% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CLB.

Core Laboratories issued an update on its third quarter 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $0.13-$0.18 for the period, compared to the consensus estimate of $0.20. The company issued revenue guidance of $123.00 million-$129.00 million, compared to the consensus revenue estimate of $125.12 million.

60 employees have rated Core Laboratories Chief Executive Officer David M. Demshur on Glassdoor.com. David M. Demshur has an approval rating of 36% among the company's employees. This puts David M. Demshur in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Core Laboratories investors own include CA (CA), BlackRock (BLK), Starbucks (SBUX), Micron Technology (MU), Chipotle Mexican Grill (CMG), Endologix (ELGX), Intel (INTC), Netflix (NFLX), AT&T (T) and Gilead Sciences (GILD).

Core Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "CLB."

Core Laboratories' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Boston Trust Walden Corp (4.30%), Van ECK Associates Corp (4.14%), State Street Corp (2.80%), Douglas Lane & Associates LLC (1.19%), Congress Asset Management Co. MA (1.10%) and Sei Investments Co. (1.04%). Insiders that own company stock include Jan Willem Sodderland, Lawrence Bruno and Mark F Elvig.
View institutional ownership trends.

Shares of CLB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLB stock can currently be purchased for approximately $16.33.

Core Laboratories (NYSE:CLB) has a market capitalization of $756.57 million and generates $470.25 million in revenue each year. The oil and gas company earns $19.73 million in net income (profit) each year or $0.19 on an earnings per share basis.

The company employs 3,700 workers across the globe.

Core Laboratories was founded in 1936.

Core Laboratories' mailing address is STRAWINSKYLAAN 913 TOWER A LEVEL 9, AMSTERDAM P7, 1077 XX. The official website for the company is www.corelab.com. The oil and gas company can be reached via phone at (120) 420-3191 or via email at investor.relations@corelab.com.